Early life intervention with glucocorticoids has negative effects on motor development and neuropsychological function in 14-17year-old adolescents

Psychoneuroendocrinology

Volumn 38, Issue 7, 2013, Pages 975-986

  Ter Wolbeek, Maike ^a   De Sonneville, Leo M J ^b   De Vries, Willem B ^a   Kavelaars, Annemieke ^a,c   Veen, Sylvia ^d   Kornelisse, René F ^e   Van Weissenbruch, Mirjam ^f   Baerts, Wim ^a,g   Liem, Kian D ^h   Van Bel, Frank ^a   Heijnen, Cobi J ^a,c  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^f VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^g ISALA HOSPITAL   (Netherlands)

^h RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Adolescence; Dexamethasone; Early life; Follow up; Glucocorticoids; Hydrocortisone; Motor development; Neonatal; Neuropsychology; Outcome

Indexed keywords

DEXAMETHASONE; GLUCOCORTICOID; HYDROCORTISONE;

ADOLESCENT; ALERTNESS; ARTICLE; ARTIFICIAL VENTILATION; COGNITION; COHORT ANALYSIS; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; EARLY INTERVENTION; EMOTION; FEMALE; GESTATIONAL AGE; HUMAN; INFANT; INTELLIGENCE; INTELLIGENCE QUOTIENT; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MENTAL FUNCTION; MOTOR DEVELOPMENT; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; NEUROLOGIC DISEASE; NEUROPSYCHOLOGICAL TEST; NEWBORN; OBSERVATIONAL STUDY; PREMATURITY; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER; RECOGNITION; SEX DIFFERENCE; SPECIAL EDUCATION; TASK PERFORMANCE; TREATMENT DURATION; TREATMENT OUTCOME; VISUOMOTOR COORDINATION;

ADOLESCENT; ATTENTION; BRONCHOPULMONARY DYSPLASIA; DEXAMETHASONE; EDUCATIONAL STATUS; EXECUTIVE FUNCTION; FEMALE; GLUCOCORTICOIDS; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; MALE; MOTOR SKILLS; NEUROPSYCHOLOGICAL TESTS;

EID: 84877927006     PISSN: 03064530     EISSN: 18733360     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2012.10.001     Document Type: Article

References (50)

1. Allin M., Matsumoto H., Santhouse A.M., Nosarti C., AlAsady M.H., Stewart A.L., Rifkin L., Murray R.M. Cognitive and motor function and the size of the cerebellum in adolescents born very pre-term. Brain 2001, 124:60-66.
2. Barrington K.J. The adverse neuro-developmental effects of postnatal steroids in the preterm infant: a systematic review of RCTs. BMC Pediatr. 2001, 1:1.
3. Benders M.J., Groenendaal F., van Bel F., Ha Vinh R., Dubois J., Lazeyras F., Warfield S.K., Hüppi P.S., de Vries L.S. Brain development of the preterm neonate after neonatal hydrocortisone treatment for chronic lung disease. Pediatr. Res. 2009, 66:555-559.
4. Brown E.S. Effects of glucocorticoids on mood, memory, and the hippocampus. Treatment and preventive therapy. Ann. N.Y. Acad. Sci. 2009, 1179:41-55.
5. Comparison chart: Adrenal Cortical Steroids Drug Facts and Comparisons 1997, Facts and Comparisons, Inc., St. Louis, pp. 122-128. 5th ed.
6. Crotty K.C., Ahronovich M.D., Baron I.S., Baker R., Erickson K., Litman F.R. Neuropsychological and behavioral effects of postnatal dexamethasone in extremely low birth weight preterm children at early school age. J. Perinatol. 2012, 32:139-146.
7. De Jong S.E., Groenendaal F., van Bel F., Rademaker K.J. Pulmonary effects of neonatal hydrocortisone treatment in ventilator-dependent preterm infants. Int. J. Pediatr. 2011, 783-893.
8. De Kloet E.R., Vreugdenhil E., Oitzl M.S., Joëls M. Brain corticosteroid receptor balance in health and disease. Endocr. Rev. 1998, 19:269-301.
9. Dennis M., Francis D.J., Cirino P.T., Schachar R., Barnes M.A., Fletcher J.M. Why IQ is not a covariate in cognitive studies of neurodevelopmental disorders. J. Int. Neuropsychol. Soc. 2009, 15:331-343.
10. de Sonneville L.M.J. Amsterdam neuropsychological tasks: a computer-aided assessment program. Cognitive Ergonomics, Clinical Assessment and Computer-assisted Learning: Computers in Psychology 1999, vol. 37:187-203.
11. de Vries W.B., Karemaker R., Mooy N.F., Strengers J.L., Kemperman H., Baerts W., Veen S., Visser G.H., Heijnen C.J., van Bel F. Cardiovascular follow-up at school age after perinatal glucocorticoid exposure in prematurely born children: perinatal glucocorticoid therapy and cardiovascular follow-up. Arch. Pediatr. Adolesc. Med. 2008, 162:738-744.
12. Doyle L.W., Ehrenkranz R.A., Halliday H.L. Postnatal hydrocortisone for preventing or treating bronchopulmonary dysplasia in preterm infants: a systematic review. Neonatology 2010, 98:111-117.
13. Giedion A., Haefliger H., Dangel P. Acute pulmonary X-ray changes in hyaline membrane disease treated with artificial ventilation and positive end-expiratory pressure (PEP). Pediatr. Radiol. 1973, 1:145-152.
14. Gross S.J., Anbar R.D., Mettelman B.B. Follow-up at 15 years of preterm infants from a controlled trial of moderately early dexamethasone for the prevention of chronic lung disease. Pediatrics 2005, 15:681-687.
15. Halliday H.L. Use of steroids in the perinatal period. Paediatr. Respir. Rev. 2004, 5:S321-S327.
16. Henderson S.E., Sugden D.A. Movement Assessment Battery For Children 1992, Psychological Corporation, London, UK.
17. Henderson S.E., Sugden D.A., Barnett A.L. Movement Assessment Battery for Children-2 (Dutch Manual) 2007, Pearson Assessment, London, UK.
18. Iwata S., Nakamura T., Hizume E., Kihara H., Takashima S., Matsuishi T., Iwata O. Qualitative brain MRI at term and cognitive outcomes at 9 years after very preterm birth. Pediatrics 2012, 129:e1138-e1147.
19. Jones R.A. Randomized, controlled trial of dexamethasone in neonatal chronic lung disease: 13- to 17-year follow-up study: I. Neurologic, psychological, and educational outcomes. Pediatrics 2005, 16:370-378. Collaborative Dexamethasone Trial Follow-up Group.
20. Kaempf J.W., Campbell B., Sklar R.S., Arduza C., Gallegos R., Zabari M., Brown A., McDonald J.V. Implementing potentially better practices to improve neonatal outcomes after reducing postnatal dexamethasone use in infants born between 501 and 1250 grams. Pediatrics 2003, 111:e534-e541.
21. Kamphuis P.J., Bakker J.M., Broekhoven M.H., Kunne C., Croiset G., Lentjes E.G., Tilders F.J., van Bel F., Wiegant V.M. Enhanced glucocorticoid feedback inhibition of hypothalamo-pituitary-adrenal responses to stress in adult rats neonatally treated with dexamethasone. Neuroendocrinology 2002, 76:158-169.
22. Karemaker R., Heijnen C.J., Veen S., Baerts W., Samsom J., Visser G.H., Kavelaars A., van Doornen L.J., van Bel F. Differences in behavioral outcome and motor development at school age after neonatal treatment for chronic lung disease with dexamethasone versus hydrocortisone. Pediatr. Res. 2006, 60:745-750.
23. Karemaker R., Kavelaars A., ter Wolbeek M., Tersteeg-Kamperman M., Baerts W., Veen S., Samsom J.F., Visser G.H., van Bel F., Heijnen C.J. Neonatal dexamethasone treatment for chronic lung disease of prematurity alters the hypothalamus-pituitary-adrenal axis and immune system activity at school age. Pediatrics 2008, 121:e870-e878.
24. Karemaker R., Karemaker J.M., Kavelaars A., Tersteeg-Kamperman M., Baerts W., Veen S., Samsom J.F., van Bel F., Heijnen C.J. Effects of neonatal dexamethasone treatment on the cardiovascular stress response of children at school age. Pediatrics 2008, 122:978-987.
25. Kaufman A.S., Kaufman J.C., Balgopal R., McLean J.E. Comparison of three WISC-III short forms: weighing psychmetric clinical, and practical factors. J. Clin. Child Psychol. 1996, 97-105.
26. Korkmaz B. Theory of mind and neurodevelopmental disorders of childhood. Pediatr. Res. 2011, 69:101R-108R.
27. Kort W., Schittekatte M., Dekker P.H., Verhaeghe P., Compaan E.L., Bosmans M., Vermeier G. WISC-III NL Handleiding en Verantwoording 2005, The Psychological Corporation, London.
28. Lazeron R.H., de Sonneville L.M., Scheltens P., Polman C.H., Barkhof F. Cognitive slowing in multiple sclerosis is strongly associated with brain volume reduction. Mult. Scler. 2006, 12:760-768.
29. Lee B.H., Stoll B.J., McDonald S.A., Higgins R.D. Neurodevelopmental outcomes of extremely low birth weight infants exposed prenatally to dexamethasone versus betamethasone. Pediatrics 2008, 121:289-296.
30. Lindström K., Lindblad F., Hjern A. Preterm birth and attention-deficit/hyperactivity disorder in schoolchildren. Pediatrics 2011, 127:858-865.
31. Lodygensky G.A., Rademaker K., Zimine S., Gex-Fabry M., Lieftink A.F., Lazeyras F., Groenendaal F., de Vries L.S., Huppi P.S. Structural and functional brain development after hydrocortisone treatment for neonatal chronic lung disease. Pediatrics 2005, 116:1-7.
32. McArthur S., McHale E., Gillies G.E. The size and distribution of midbrain dopaminergic populations are permanently altered by perinatal glucocorticoid exposure in a sex- region- and time-specific manner. Neuropsychopharmacology 2007, 32:1462-1476.
33. Murphy B.P., Inder T.E., Huppi P.S., Warfield S., Zientara G.P., Kikinis R., Jolesz F.A., Volpe J.J. Impaired cerebral cortical gray matter growth after treatment with dexamethasone for neonatal chronic lung disease. Pediatrics 2001, 107:217-221.
34. Nieoullon A., Coquerel A. Dopamine: a key regulator to adapt action, emotion, motivation and cognition. Curr. Opin. Neurol. 2003, 16:S3-S9.
35. Onland W., Offringa M., De Jaegere A.P., van Kaam A.H. Finding the optimal postnatal dexamethasone regimen for preterm infants at risk of bronchopulmonary dysplasia: a systematic review of placebo-controlled trials. Pediatrics 2009, 123:367-377.
36. O'Shea T.M., Washburn L.K., Nixon P.A., Goldstein D.J. Follow-up of a randomized, placebo-controlled trial of dexamethasone to decrease the duration of ventilator dependency in very low birth weight infants: neurodevelopmental outcomes at 4 to 11 years of age. Pediatrics 2007, 120:594-602.
37. Papile L.A., Burstein J., Burstein R., Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500gm. J. Pediatr. 1978, 92:529-534.
38. Parikh N.A., Lasky R.E., Kennedy K.A., Moya F.R., Hochhauser L., Romo S., Tyson J.E. Postnatal dexamethasone therapy and cerebral tissue volumes in extremely low birth weight infants. Pediatrics 2007, 119:265-272.
39. Rademaker K.J., Rijpert M., Uiterwaal C.S., Lieftink A.F., van Bel F., Grobbee D.E., de Vries L.S., Groenendaal F. Neonatal hydrocortisone treatment related to 1H-MRS of the hippocampus and short-term memory at school age in preterm born children. Pediatr. Res. 2006, 59:309-313.
40. Rowbotham I., Pit-ten Cate I.M., Sonuga-Barke E.J., Huijbregts S.C. Cognitive control in adolescents with neurofibromatosis type 1. Neuropsychology 2009, 23:50-60.
41. Sauro M.D., Jorgensen R.S., Pedlow C.T. Stress, glucocorticoids, and memory: a meta-analytic review. Stress 2003, 6:235-245.
42. Shinwell E.S. Current dilemmas in postnatal steroid therapy for chronic lung disease in preterm infants. Biol. Neonate 2003, 84:96-100.
43. Shinwell E.S., Lerner-Geva L., Lusky A., Reichman B. Less postnatal steroids, more bronchopulmonary dysplasia: a population-based study in very low birthweight infants. Arch. Dis. Child. Fetal Neonatal Ed. 2007, 92:F30-F33.
44. Slotkin T.A., Kreider M.L., Tate C.A., Seidler F.J. Critical prenatal and postnatal periods for persistent effects of dexamethasone on serotonergic and dopaminergic systems. Neuropsychopharmacology 2006, 31:904-911.
45. Squire L.R. Memory and the hippocampus: a synthesis from findings with rats, monkeys, and humans. Psychol. Rev. 1992, 99:195-231.
46. Van der Heide-Jalving M., Kamphuis P.J., van der Laan M.J., Bakker J.M., Wiegant V.M., Heijnen C.J., Veen S., van Bel F. Short- and long-term effects of neonatal glucocorticoid therapy: is hydrocortisone an alternative to dexamethasone?. Acta Paediatr. 2003, 92:827-835.
47. Van Kooij B.J., Benders M.J., Anbeek P., Van Haastert I.C., de Vries L.S., Groenendaal F. Cerebellar volume and proton magnetic resonance spectroscopy at term, and neurodevelopment at 2 years of age in preterm infants. Dev. Med. Child Neurol. 2011, 54:260-266.
48. Walsh M.C., Yao Q., Horbar J.D., Carpenter J.H., Lee S.K., Ohlsson A. Changes in the use of postnatal steroids for bronchopulmonary dysplasia in 3 large neonatal networks. Pediatrics 2006, 118:e1328-e1335.
49. Wróbel A., Zebrowska-Łupina I., Wielosz M. Dexamethasone reduces locomotor stimulation induced by dopamine agonists in mice. Pharmacol. Rep. 2005, 57:451-457.
50. Yeh T.F., Lin Y.J., Lin H.C., Huang C.C., Hsieh W.S., Lin C.H., Tsai C.H. Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity. N. Engl. J. Med. 2004, 25:1304-1313.